Johnson L N, Stetson S W, Krohel G B, Cipollo C L, Madsen R W
Neuro-ophthalmology Unit, Mason Eye Institute, University of Missouri, Columbia, MO 65212, USA.
Am J Ophthalmol. 2000 Mar;129(3):367-71. doi: 10.1016/s0002-9394(99)00362-1.
To assess the relationship of aspirin use and ischemic cranial nerve palsies among patients with diabetes mellitus and hypertension.
This retrospective case-control study involved 100 patients with ischemic cranial nerve palsies in association with diabetes, hypertension, or both (palsy cases) and 163 age-matched and sex-matched patients with diabetes, hypertension, or both but without ischemic cranial nerve palsies (nonpalsy control subjects). Comparisons were made with respect to duration of diabetes, dose and duration of aspirin use, dose and duration of tobacco use, and presence of cardiac or cerebrovascular disease.
There were 20 oculomotor, 33 trochlear, 37 abducens, and 10 facial nerve palsy cases. The median duration of diabetes was 6 years for cases and 7 years for control subjects. There were 34 cases (34%) who had used aspirin for a mean duration of 5.5 years before the onset of the cranial nerve palsy and 49 control subjects (30.1%) who had used aspirin for a mean duration of 4.3 years. There were no significant differences between cases and control subjects for duration of diabetes (P =.94); aspirin use (P =.51), duration (P =.50), and dosage (P =.89); tobacco use (P =.73) and consumption (P =.45); and proportion of cardiac disease (P =.17). Cerebrovascular disease was significantly less common among palsy cases than nonpalsy control subjects (P<.001). There was no significant difference in the odds of a patient having cranial nerve palsy in the aspirin group compared with the nonaspirin group (odds ratio, 1.12; 95% confidence interval, 0.70-2.04).
Aspirin use was not associated with a reduced rate of ischemic third, fourth, sixth, and seventh nerve palsies among patients with diabetes mellitus and hypertension. Aspirin appears to be ineffective in preventing ischemic third, fourth, sixth, and seventh cranial nerve palsies. Patients with ischemic cranial nerve palsy have a significantly lower rate of strokes and transient ischemic attacks than patients who have diabetes or hypertension but who do not have a history of cranial nerve palsy.
评估糖尿病和高血压患者中阿司匹林使用与缺血性脑神经麻痹之间的关系。
这项回顾性病例对照研究纳入了100例伴有糖尿病、高血压或两者皆有的缺血性脑神经麻痹患者(麻痹病例组)以及163例年龄和性别匹配的患有糖尿病、高血压或两者皆有但无缺血性脑神经麻痹的患者(非麻痹对照组)。对糖尿病病程、阿司匹林使用剂量和时间、烟草使用剂量和时间以及心脏或脑血管疾病的存在情况进行了比较。
有20例动眼神经、33例滑车神经、37例展神经和10例面神经麻痹病例。病例组糖尿病的中位病程为6年,对照组为7年。有34例(34%)在脑神经麻痹发作前平均使用阿司匹林5.5年,49例对照组患者(30.1%)平均使用阿司匹林4.3年。病例组和对照组在糖尿病病程(P = 0.94)、阿司匹林使用情况(P = 0.51)、使用时间(P = 0.50)和剂量(P = 0.89)、烟草使用情况(P = 0.73)和消耗量(P = 0.45)以及心脏病比例(P = 0.17)方面均无显著差异。与非麻痹对照组相比,麻痹病例组中脑血管疾病明显较少见(P<0.001)。与非阿司匹林组相比,阿司匹林组患者发生脑神经麻痹的几率无显著差异(优势比,1.12;95%置信区间,0.70 - 2.04)。
在糖尿病和高血压患者中,阿司匹林使用与缺血性动眼神经、滑车神经、展神经和面神经麻痹发生率降低无关。阿司匹林似乎在预防缺血性动眼神经、滑车神经、展神经和面神经麻痹方面无效。与患有糖尿病或高血压但无脑神经麻痹病史的患者相比,缺血性脑神经麻痹患者中风和短暂性脑缺血发作的发生率明显较低。